Investor
Relations
Recordati has been at the forefront of life-enhancing and life-changing medicines for the last 100 years, and has been listed on Italian stock exchange since 1984.
Underpinned by a history of strong financial delivery, we will continue to grow from within, capture opportunities within our own pipeline, and identify opportunities to bring in new treatments through acquisitions across all our businesses.
Investor
Relations
Recordati has been at the forefront of life-enhancing and life-changing medicines for the last 100 years, and has been listed on Italian stock exchange since 1984.
Underpinned by a history of strong financial delivery, we will continue to grow from within, capture opportunities within our own pipeline, and identify opportunities to bring in new treatments through acquisitions across all our businesses.
Presentation to the financial community: 2025-2027 Recordati Three Year Plan presentation
The Recordati management team will host a meeting with the financial community to present the 2025-2027 three-year plan update tomorrow, 29th April, at 4:00 p.m. CET (3:00 p.m. GMT)
In person:
Borsa Italiana – Milan (Italian Stock Exchange) piazza Affari, 6 Milan
- 3:30 pm CET – Welcome & Registration
- 4:00 pm CET – Presentation
Virtual attendance:
The live webcast will also be available at the following link
Conference Call Details:
Dial in number(s)
USA Local: +1 786 697 3501
USA Toll Free: 866 580 3963
Rome: +39 06 83360400
UK-Wide: +44 (0) 33 0551 0200
Password: Quote Recordati when prompted by the operator
Upcoming Events
No upcoming events found.
Date:
April 29, 2025
-
April 29, 2025
Annual Shareholders’ Meeting to approve Recordati S.p.A.’s 2024 financial statements and to appoint Board of Directors
Date:
April 29, 2025
-
April 29, 2025
Recordati: 2025-2027 Plan Presentation
Location:
Milan
Date:
May 8, 2025
-
May 8, 2025
Board of Directors’ meeting to approve the 2025 first quarter results, as additional voluntary financial reporting
Revenue trend 2020 - 2024 (million Euro)
Revenue by business unit 2020 - 2024 (million Euro)
Total Revenue split by Therapeutica area - FY 2024
(SPC 64.4%, Rare Disease 35.6%)
Note: Total OTC of € 334.9 million in FY 2024 and € 331.3 million in FY 2023
Pharmaceutical revenue (excluding Chemicals) split by Geographic - FY 2024
Key P&L Data
|
(million Euro)
|
FY 2024
|
|
FY 2023
|
|
FY 2022
|
|
FY 2021
|
|
FY 2020
|
|---|---|---|---|---|---|---|---|---|---|
(million Euro)
Revenue
|
FY 2024
2,341.6
|
FY 2023
2,082.3
|
FY 2022
1,853.3
|
FY 2021
1,580.1
|
FY 2020
1,448.9
|
||||
(million Euro)
Gross Profit
as % of revenue |
FY 2024
1,600.3
68.3 |
FY 2023
1,422.6
68.3 |
FY 2022
1,286.6
69.4 |
FY 2021
1,152.3
72.9 |
FY 2020
1,042.0
71.9 |
||||
(million Euro)
Adjusted Gross Profit (1)
as % of revenue |
FY 2024
1,637.8
69.9 |
FY 2023
1,481.6
71.1 |
FY 2022
1,336.4
72.1 |
FY 2021
1,152.3
72.9 |
FY 2020
1,042.0
71.9 |
||||
(million Euro)
Operating Income (EBIT)
as % of revenue |
FY 2024
638.9
27.3 |
FY 2023
558.0
26.8 |
FY 2022
437.3
23.6 |
FY 2021
490.2
31.0 |
FY 2020
469.0
32.4 |
||||
(million Euro)
Adjusted Operating Income (Adj. EBIT) (2)
as % of revenue |
FY 2024
684.4
29.2 |
FY 2023
626.6
30.1 |
FY 2022
536.1
28.9 |
FY 2021
504.6
31.9 |
FY 2020
469.0
32.4 |
||||
(million Euro)
Net Income
as % of revenue |
FY 2024
416.5
17.8 |
FY 2023
389.2
18.7 |
FY 2022
312.3
16.9 |
FY 2021
386.0
24.4 |
FY 2020
355.0
24.5 |
||||
(million Euro)
Adjusted Net Income (3)
as % of revenue |
FY 2024
568.9
24.3 |
FY 2023
524.6
25.2 |
FY 2022
473.3
25.5 |
FY 2021
424.6
26.9 |
FY 2020
410.4
28.3 |
||||
(million Euro)
EBITDA (4)
as % of revenue |
FY 2024
865.8
37.0 |
FY 2023
769.6
37.0 |
FY 2022
672.8
36.3 |
FY 2021
602.3
38.1 |
FY 2020
569.3
39.3 |
1) Adjusted gross profit: Gross profit adjusted by the impact of non-cash charges arising from the allocation of the purchase price of EUSA Pharma and Enjaymo® to the gross margin of acquired inventory according to IFRS 3
2) Adjusted Operating Income: Net income before income taxes, financial income and expenses and non-recurring items, non-cash charges arising from the allocation of the purchase price of EUSA Pharma and Enjaymo® to the gross margin of acquired inventory according to IFRS 3.
3) Adjusted Net Income: Net income excluding the amortization and write-downs of intangible assets (except software) and goodwill, non-recurring items, non-cash charges arising from the allocation of the purchase price of EUSA Pharma and Enjaymo® to the gross margin of acquired inventory pursuant to IFRS 3, and monetary net gains/losses from hyperinflation (IAS 29), net of tax effects.
4) EBITDA: Net income before income taxes, financial income and expenses, depreciation, amortization and write-downs of property, plant and equipment, intangible assets and goodwill, non-recurring items and non-cash charges arising from the allocation of the purchase price of EUSA Pharma and Enjaymo® to the gross margin of acquired inventory according to IFRS 3
Balance Sheet at December 2023 (million Euro)
Net Debt - FY 2020 - 2024 (million Euro)
Net Debt / EBITDA1 - FY 2022 - 2024 (million Euro)
1) EBITDA: Net income before income taxes, financial income and expenses, depreciation, amortization and write-downs of property, plant and equipment, intangible assets and goodwill, non-recurring items and non-cash charges arising from the allocation of the purchase price of EUSA Pharma and Enjaymo® to the gross margin of acquired inventory according to IFRS 3
*Pro-forma calculated by adding Enjaymo’s® estimated contribution for the first eleven months of fiscal year 2024 (when it still was propriety of Sanofi) to EBITDA
Free Cash Flow1 - FY 2022 - 2024 (million Euro)
1) Operating cash flow excluding financing items, milestones, dividends, purchases of treasury shares net of proceeds from exercise of stock options
